China just made it easier—and more rewarding—for innovative therapies to access its vast market.
On July 1, 2025, China's National Healthcare Security Administration and National Health Commission jointly released a powerful policy framework:
《Measures to Support the High-Quality Development of Innovative Drugs》—a full-chain push covering R&D, market access, hospital inclusion, and payment innovation.
Why this matters for international biotech:
A new Commercial Health Insurance Drug List is being introduced—offering a parallel track to basic public insurance and unlocking new payment pathways.
Companies can now apply for both public and commercial insurance listings simultaneously, expediting access and reimbursement.
Regulatory and reimbursement pathways are aligning, with expanded support for real-world data, parallel NMPA-FDA strategies, and commercial insurance-backed trials.
A focus on data sharing, joint supervision, and multi-tiered payment models creates unprecedented opportunity for biotechs with novel therapies.
For international sponsors, this creates a perfect window to launch trials in China—accessing large patient populations, achieving 2-3x faster enrollment, and benefiting from up to 80% cost savings.
With China's innovative drug market expected to exceed ¥2 trillion (~$275B) by 2030, and a record wave of licensing deals in H1 2025, the ecosystem is primed for collaboration and scale.
If your company is looking to expand into China or include China in an MRCT, contact suling.zhang@gcp-clinplus.com for a customized feasibility and cost estimate.
